Review Pulmonary- Allergy, Dermatological, Gastrointestinal & Arthritis: Current therapies for peptic ulcer disease

References

• MODER KP: Recent advances in anti-ulcer agents. Curr.
   Google Scholar
• • Opin. Thera. Patents (1993) 3(9):1305–1312.
   Google Scholar
• Scrip (1995) 2010:26.
   Google Scholar
• Scrip (1995) 2000:6–7.
   Google Scholar
• Scrip (1995) 1949:23.
   Google Scholar
• Scrip (1995) 2050:3.
   Google Scholar
• Scrip (1995) 2023:23.
   Google Scholar
• Pharma Japan (1995) 1463:5.
   Google Scholar
• SAC-IS G, SHIN JM, BRIVING C, WALLMARK B, HERSEY S:
   Google Scholar
• •• The pharmacology of the gastric acid pump: the II*,ATPase. Ann. Rev. Pharmacol. Toxicol. (1995) 35:277–305.
   Google Scholar
• HIRAI M, AZUMA T, ITO S, KATO T, KOHLY Y: A proton pump inhibitor, E3810, has antibacterial activity through binding to Helicobacter pylon. J. Gastroenterol. (1995) 30:461–464.
   PubMedGoogle Scholar
• NAGATA K, TAKAGI E, TSUDA, M, NAKAZAWA T, SATOH H, NAKAO MN, OKAMURA H, TAMURA T: Inhibitory action of lansoprazole and its analogs against Helico-bacter pylori: inhibition of growth is not related to inhibition of urease. Antimicrob. Agents Chemother. (1995) 39(2):567–570.
   PubMedGoogle Scholar
• KAMINSKI JJ, PULCHALSKI C, SOLOMON DM, RIZVI RK, CONN DJ: Conformational considerations and the anti-ulcer activity of substituted imidazo[1,2-aipyridines and related analogues. J. Med. Chem. (1989) 32:1686–1700.
   PubMedGoogle Scholar
• BROOM C, EAGLES, STEEL S, PUE M, LAROCHE J: Com-parison of the antisecretory effect of the novel revers-ible proton pump inhibitor SK&F 96067 and ranitidine. Gastroenterol. (1993) 104:A46.
   Google Scholar
• WOMACK A: Dow Jones News (October 26, 1995).
   Google Scholar
• WARREN JR, MARSHALL BJ: Unidentified curved bacillus on the gastric epithelium in active chronic gastritis. Lancet (1983) 1:1273–1275.
   PubMed Web of Science ®Google Scholar
• LEE A: New microbiological features. Eur.J. Gastroenterol. Hepat. (1995) 7:303–310.
   PubMedGoogle Scholar
• SALASPURO M: Helicobacter pylori alcohol dehydro-genase. EXS (Switzerland) (1994) 71:185–195.
   Google Scholar
• SUERBAUM S, WADSTROM T: Bacterial pathogenic fac-tors. Curr. Opin. Gastroenterol. (1995) 11(S1):11–15.
   Google Scholar
• MENDZ GL, HAZELL SL: Amino acid utilisation by Hell-cobacter pylori. Inter. J. Biocbem . Cell Biol. (1995) 27(10):1085–1093.
   PubMedGoogle Scholar
• VINCENT P: Transmission and acquisition of Helkobacter pylori infection: evidences and hypothesis. Btomed. Pharmacother. (1995) 49:11–18.
   PubMedGoogle Scholar
• GRAHAM DY, KIMURA K, SHIMOYAMA T, TAKEMOTO T: Helicobacter pylori infection in Japan: current status and future options. Eur. J. Gastroenterol. Hepat. (1994) 6\(Suppl. 1):S1–S4.
   Google Scholar
• FIGURA N: Progress in defining the inflammatory cas-cade. Eur. J. Gastroenterol. Hepat. (1995) 7:296–302.
   PubMed Web of Science ®Google Scholar
• LAMBERT JR, UN SK, ARANDRA-MICHEL J: Helicobacter pylori. Scand.1 Gastroenterol. (1995) 30(S208):33–46.
   Google Scholar
• MEGRAUD F: Toxic factors of Helicobacter pylorL Eur. Gastroenterol. Hepat. (1994) 6\(Suppl. 1):55–S10.
   Google Scholar
• LICHTENBERGER LM, DIAL EJ, ROMERO JJ, LECHAGO J, JAROBE LA, WOLFE MM: Role of luminal ammonia in the development of gastropathy and hypergastrinemia in the rat. Gastroenterology (1995) 108(2):320–329.
   PubMed Web of Science ®Google Scholar
• RO1NE RP, SALMELA KS, SALAPURO M: Helicobacter in-fection and gastric ethanol metabolism. Ann. Med. (1995) 27(9:583–588.
   PubMedGoogle Scholar
• EL OMAR EM, PENMAN ID, ARDILL JES, MCCOLL EEL: A substantial proportion of non-ulcer dyspepsia patients have the same abnormality of acid secretion as duode-nal ulcer patients. Gut (1995) 36(4):534–538.
   PubMedGoogle Scholar
• EL OMAR ME, PENMAN ID, ARDILL JES, CHITTAJALLU RS, HOWIE C, MCCOLL EEL: Helicobacter pylori infection and abnormalities of acid secretion in patients with duodenal ulcer disease. Gastroent. (1995) 109(9:681–691.
   Google Scholar
• PARENTE F, MACONI G, SANGALETTI 0, MINGUZZI M, VAGO L, PORRO GB: Behaviour of acid secretion, gastrin release, serum pepsinogen I, and gastric emptying of liquids over six months from eradication of Helicobac-ter pylori in duodenal ulcer patients. A controlled study. Gut (1995) 37:210–215.
   PubMed Web of Science ®Google Scholar
• CALAM J: Helicobacter pylori, acid and gastrin. Eur. J. Gastroenterol Hepat (1995) 7(4):310–317.
   PubMedGoogle Scholar
• PHULL PS, GREEN CJ, JACYNA MR: A radical view of the stomach: the role of oxygen-derived free radicals and anti-oxidants in gastroduodenal disease. Eur. J. Gas-troenterol. Hepat (1995) 7:265–274.
   PubMed Web of Science ®Google Scholar
• FALK GW: Current status of Helicobacter pylori in peptic ulcer disease. Cleve. Clin .J. Med. (1995) 6(2): 95–104.
   Google Scholar
• DELANEY BC: Role of Helicobacter pylori in gastrointestinal disease: implications for primary care of a revolution in management of dyspepsia. Br. J. Gen. Prac. (1995) 45:489–494.
   PubMedGoogle Scholar
• JOHANSEN HK, NORGAARD A, ANDERSEN LP, JENSEN AP, NIELSEN H, HOIBY N: Cross-reactive antigens shared by Pseudomonas aeruginosa, Helicobacter pylori, Cam-pylobacter fejuni, and Haemopbilus influenzae may cause false-positive titers of antibody to H. pylori. Clin. Diagn. Lab. Immun. (1995) 2:149–155,
   PubMedGoogle Scholar
• FUJIOKA T, URIBE RU, KUBOTA T, MURAKAMI K, KAWASAKI H, NASU M: Establishment of an animal model for chronic gastritis with Helicobacter pylori: potential model for long-term observations. Eur. J. Gastroenterol. Hepat (1995) 7\(Suppl. 1):S35–S38.
   Google Scholar
• GRAHAM DY, OPEKUN AR, KLEIN PD: Clarithromycin for the eradication of Helicobacter pylori. J. Clin. Gastroen-terol. (1993) 16:292–294.
   PubMed Web of Science ®Google Scholar
• HUNT RH, MALFERTHEINER P, YEOMANS ND, HAWKEY
   Google Scholar
• • CJ, HOWDEN CW: Critical issues in the pathophysiology and management of peptic ulcer disease. Eur.J. Gastroen-terol. Hepat (1995) 7:685–699.
   Google Scholar
• ALASSI MT, GENTA RM, KARTTUNEN TJ, COLE RA, GRA-HAM DY: Azithromycin triple therapy for Helicobacter pylori infection - azithromycin, tetracycline and bis-muth. Am. J. Gastroenterol. (1995) 90(3):403–405.
   PubMedGoogle Scholar
• BERSTAD A, BERSTAD K, WILHELMSEN I, HATEBARKK JG, NESJE LB, HAUSKEN T: Spiramycin in triple therapy of Helicobacter pylori-associated peptic ulcer disease. An open pilot study with 12-month follow-up. Aliment. Pharmaco. Therap. (1995) 95(2)197–200.
   Google Scholar
• WILHELMSEN I, WEBERG R, BERSTAD K, HAUSKEN T, HUNDAL 0, BERSTAD A: Helicobacterpylori eradication with bismuth subnitrate, oxytetracycline and metroni-dazole in patients with peptic ulcer disease. Hepatogas-troenterol. (Germany) (1994) 41(1):43–47.
   PubMedGoogle Scholar
• HUNT RH, MOHAMED AH: The current role of Helico-bacter pylori eradication in clinical practice. Scand. J. Gastroenterol (1995) 30(S208):47–52.
   Google Scholar
• CALAM J, RAUWS EJA: Gastric physiology. Curr. Opin. Gastroenterol. (1995) 1(S1):16–20.
   Google Scholar
• GIBALDI M: Helicobacter pylori and gastrointestinal disease. J. Clin. Pharmacol. (1995) 35(7):647–654.
   PubMed Web of Science ®Google Scholar
• MARTIN DF, MAY SJ, TWEEDLE DE, HOLLANDERS D, RAVENSCROFT MM, MILLER JP: Difference in relapse rates of duodenal ulcer healing with cimetidine or tripotassium dlcitrato bismuthate. Lancet (1980) 1:7–10.
   Google Scholar
• LEE Fl, SAMLOFF IM, HARDMAN M: Comparison of tripo-tassium dicitrato bismuthate tablets with ranitidine in healing and relapse of duodenal ulcers. Lancet (1985) 1:1299–1302.
   PubMed Web of Science ®Google Scholar
• MARSHALL BJ, ARMSTRONG JA, FRANCIS GJ, NOKES NT, WEE SH: The antibacterial action of bismuth in relation to Campykthacter pyloridis colonisation and gastritis. Digestion (1987) 37\(Suppl. 2):16–30.
   Google Scholar
• Scrip (1995) 2048: 17.
   Google Scholar
• SONNENBERG A, TOWNSEND WE: Costs of duodenal ulcer therapy with antibiotics. Arch. Intern. Med. (1995) 155(9):922–928.
   PubMedGoogle Scholar
• FENDRICK AM, CHERNEW ME, HIRTH RA, BLOOM BS:
   Google Scholar
• • Alternative management strategies for patients with suspected peptic ulcer disease. Ann. Intern. Med. (1995) 123(4):260–268.
   Google Scholar
• O'CONNER HJ: Eradication of Helicobacter pylori. Eur. J. Gastroenterol. Hepat. (1994) 6\(Suppl. 1):S113–S119.
   Google Scholar
• THOMSON ABR, WILLIAMS CN: Helicobacter pylori: ba-sic mechanisms to clin1c•1 cure. Can. J. Gastroenterol. (1995) 9(4:91–95.
   Google Scholar
• SMITH MA, EDWARDS DI: Redox potential and oxygen concentration as factors in the susceptibility of Helico-bacter pylori in nkroheterocyclic drugs. J. Antimicrob. Chemother. (1995) 35(0:751–764.
   PubMedGoogle Scholar
• KATELARIS P: Treatment of Helicobacter pylori infec-tion. Biomed. Pharmacother. (1995) 49:5–10.
   PubMed Web of Science ®Google Scholar
• LANAS Al, REMACHA B, ESTEVA F, SAINZ R: Risk factors associated with refractory peptic ulcers. Gastroenterol. (1995) 109(4)1124–1133.
   Google Scholar
• PIPER DW: A comparative overview of the adverse effects of antiulcer drugs. Drug Safety (1995) 12(2)120–138.
   Google Scholar
• BLANC P, LIAUTARD J, GREUET J, DAURES JP, FABRE JM,
   Google Scholar
• • LARREY D, MICHEL H, MAUREL P: Effect of anti-ulcer drugs on DNA synthesis in adult normal human hepa-tocytes in culture. Hepatology (1995) 22(3):814–819.
   Google Scholar
• AYBAY C, IMIR T, OKUR H: Gen. Pbarmacol. (1995) 26(6):1413–1418.
   Google Scholar
• JASPERSEN D, KOERNER T, SCHORR W, BRENNENSTUH1 M, RASCHKA C, HAMMAR CH: Helicobacter pylori eradi-cation reduces the rate of rebleeding in ulcer hemor-rhage. Gastrointest. Endo. (1995) 41(1):5–7.
   PubMedGoogle Scholar
• HENRIKSSON AE, EDMAN AC, HELD M, WADSTROM T: Helicobacter pylori and acute bleeding peptic ulcers. Eur. J. Gastroenterol. Hepat. (1995) 7(8):769–771.
   PubMed Web of Science ®Google Scholar
• AGREUS L, ENGSTRAND L, SVARDSUDD K, NYREN 0, TIBBLIN G: Helicobacter pylori seropositivity among Swedish adults with and without abdominal symptoms - a population based epidemiologic study. Scand. J. Gastroenterol (1995) 30(8):752–757.
   PubMed Web of Science ®Google Scholar
• ELTA GH, SCHEIMAN JM, BARNETT JL, NOSTRANT TT,BEHLER EM, CRAUSE I, APPELMAN HD: Long-term follow-up of Helicobacter pylori treatment in non-ulcer dys-pepsia patients. Am. J. Gastroenterol. (1995) 90(7)1089–1093.
   Google Scholar
• KREISS C, FRIED M: Functional dyspepsia Old wine innew bottles? Schweiz Med. Wocheschr. (1994) 124(10):391–401.
   Google Scholar
• CAMMAROTA G, TUBS A, MONTALTO M, PAPA A, BRANCA G, VECCHIO FM, RENZI C, VERZI A, ARMUZZI A, PRETO-LANI S, FEDELI G, GASBARRINI G: Prevention and treat-ment of low-grade B-cell primary gastric lymphoma by anti-H. pylori therapy. J. Clin. Gastroenterol. (1995) 21(2)118–122.
   Google Scholar
• CAHILL RJ, XIA HJ, KILGALLEN C, BEATHE S, HAMILTON H, OMORAIN C: Effect of eradication of Helicobacter pylori infection on gastric epithelial cell proliferation. Digestive Disease Sci. (1995) 40(8)1627–1631.
   Google Scholar
• EIDT S, STOLTE M: The significance of Helicobacter pylori in relation to gastric cancer and lymphoma. Eur. J. Gastroenterol. Hepat. (1995) 7(4):318–321.
   PubMedGoogle Scholar
• TEE W, LAMBERT JR, DWYER B: Cytotoxin production by Helicobacter pylori from patients with upper gastroin-testinal tract diseases. J. din. Microbiol. (1995) 33(5):1203–1205.
   Google Scholar
• TAYLOR NS, FOX JG, YAN L: In vitro hepatotoxic factorIn Helicobacter bepaticus, H. pylori and other Helico-bacter species. J. Med. Microbiol. (1995) 42(10):48–52.
   PubMedGoogle Scholar
• MITCHELL HM, LEE A: Association of Helicobacter pylori with gastric cancer and observations on the detection of this bacterium in gastric cancer cases. Eur.J. Gastroen. Hepat. (1994) 6\(Suppl. 1):S11–S16.
   Google Scholar
• GRAHAM DY, GO MF, GENTA EM: Helicobacter pylori, duodenal ulcer, gastric cancer: tunnel vision or blink-ers. Ann. Med. (1995) 27(5):589–594.
   PubMed Web of Science ®Google Scholar
• LONG BW, JOHNSTON JH, WETZEL W, FLOWERS RH, HAICK A: Gastric syphilis: endoscopic and histological features mimicking lymphoma. Am. J. Gastroenterol. (1995) 90(9):1504–1507.
   PubMedGoogle Scholar
• WEAVER LT: Aspects of Helicobacter pylori infection inthe developing and developed world: Helicobacter py-lori infection, nutrition, and growth of West African Infants. Royal Soc. Tropical Med. Hygiene (1995) 89(4): 347–350.
   PubMedGoogle Scholar
• CLEMENS J, ALBERT MJ, RAO M, QADRI F, HJLTDA S, KAYB, VANLOON FPL, SACKS, PRADHAN BA, SACK RB: Impact of infection by Helicobacter pylori on the risk and severity of endemic cholera. J. Infec. Dis. (1995) 172(6):1653–1656.
   Google Scholar
• PATEL P, MENDALL MA, CARRINGTON D, STRACHAN DP,LEATHAM E, MOLINEAUX N, LEVY J, BLAKESTON C, SEY-MOUR CA, CAMM AL, NORTHFIELD TA: Helicobacter pylori infection in childhood: risk factors and effect on growth. BMJ (1995) 311(7007):711–714.
   PubMedGoogle Scholar
• REBORA A, DRAGO F, PARODI A: May Helicobacter pylori be important for dermatologists. Dermatology (1995) 191(1):6–8,
   PubMedGoogle Scholar
• BOREN T, FALK P, ROTH KA, LARSON G, NORMARK S: Attachment of Helicobacter pylori to human gastric epithelium mediated by blood group antigens. Science (1993) 262:1892–1895.
   PubMed Web of Science ®Google Scholar
• CHMIELA M, PAZIAKDOMANSKA B, WADSTROM T: At-tachment, ingestion and intracellular killing of Helico-bacter pylori by human peripheral blood mononuclear leukocytes and mouse peritoneal inflammatory macro-phages. FEMS Immun. Med. Microbiol. (1995) 10(3-4):307–316.
   PubMedGoogle Scholar
• Scrip (1995) 2058:26.
   Google Scholar
• Scrip (1995) 1990:25.
   Google Scholar
• Scrip (1995) 2007:22.
   Google Scholar
• DAVIS J: Scrip Magazine (1995) 39:43–45.
   Google Scholar
• GUSTAVSON LE, KAISER JF, EDMONDS AL, LOCKE CS, DEBARTOLO ML, SCI-INECK DW: Effects of omeprazole on concentrations of clarithromycin in plasma and gastric tissue at steady state. Antimicrob. Agents Chemother. (1995) 39(9):2078–2083.
   PubMed Web of Science ®Google Scholar
• SUNAIRI M, WATANABE K, SUZUKI T, TANAKA N, KU-WAYAMA H, NAKAJIMA M: Effects of anti-ulcer agents on antibiotic activity against Helicobacter pylori. Eur. J. Gastroenterol. Hepat. (1994) 6\(Supp1.1):S121–S124.
   Google Scholar
• MODLIN IM: To repair the fault or end the acid reign. Scand. J. Gastroenterol. (1995) 30(S210):1–5.
   PubMedGoogle Scholar
• SLOMIANY A, PIOTROWSKI J, SLOMIANY BL: Sucralfate counteracts the inhibition of gastric-mucosal mucin receptor by Helicobacter pylori lipopolysaccharide. Scand. J. Gastroenterol. (1995) 30(3210):77–81.
   Google Scholar
• GOEL A, MADAN AK: Structure-activity study on anti-in-flammatory pyrazole carboxylic add hydrazide analogs using molecular connectivity indices. J. Chem. Inf. Corn-put. Sci. (1995) 35(3):504–509.
   PubMedGoogle Scholar
• PROJAN SJ, BLACKBURN P: The bacteriocin nisin, acti-vated by chelating agents, is bactericidal for Helicobac-ter pylori in vitro: a rationale for a novel topical gastroduodenal agent.Gastroenterol.(1993)104(Suppl.):A173.
   Google Scholar
• Scrip (1995) 2042:10.
   Google Scholar
• MENDZ GL, HAZELL SL, SRINIVASAN S: Fuimarate reduc-tase: a target for therapeutic intervention against Hell-cobacter pylori. Arch. Biochem. Biophys. (1995) 321(1):153–159.
   PubMedGoogle Scholar
• MURTY VL, PIOTROWSKI J, CAZJKOWSKI A, SLOMIANY A,SLOMIANY BL: Inhibition of Helicobacter pylori glyco-sulfatase activity towards human gastric sulfomucin by a gastroprotective agent, sulglycotide. Gen. Pharmacol. (1993) 24(6):1463–1466.
   PubMedGoogle Scholar
• BARGA LL, SAROSIEK J, MARSHALL B, MCCALLUM RW,BARRET L, GUERRANT T: Gold: a new potential drug for the treatment of Helicobacter pylori infection. Gas-troenterol. (1990) 98(Suppl.) A25.
   Google Scholar
• HO B, JIANG B: The adhesion of Helicobacter pyloriextract to four mammalian cell lines. Eur. J. Gastroen-terol. Hepat. (1995) 7:121–124.
   PubMedGoogle Scholar
• STROMQVIST M, FALK P, BERGSTROM S, HANSSON L, LONNERDAL B, NORMARK S, HERNELL 0: Development of a vaccine. J. Ped. Gastroenterol. and Nutr. (1995) 21(3):288–296.
   PubMed Web of Science ®Google Scholar
• GHIARA P, MICHETTI P: Development of a vaccine. Curr.
   Google Scholar
• • Opin. Gastroenterol. (1995) 11(S1):52–56.
   Google Scholar
• TELFORD JL, GH1ARA P, DELL'ORCO M, COMANDUCII M,BURRONI D, BUGNOLI M, TECCE MF, CENSINI S, COVACCI A, XIANG Z: Gene structure of the Helicobacter pylori cytotoxin and evidence of its key role in gastric disease. J. Exp. Med. (1994) 179(5):1653–1658.
   PubMedGoogle Scholar
• BLASER MJ, PEREZPEREZ GI, KLEANTHOUS H, COVER TT.,PEEK 11M, CHYOU PH, STEMMERMANN GN, NOMURA A: Infection with Helicobacter pylori strains possessing cagA is associated with an increased risk of developing adenocarcinoma of the stomach. Cancer Res. (1995) 55(10):2111–2115.
   Google Scholar
• COVER TL, GLUPCZYNSKI T, LAGE AP, BURETTE A, TUM-MURU MKR, PEREZPEREZ GI, BLASER MJ: Serologic detec-tion of infection with cagA+ Helicobacterpylort strains. J. Clin. Micn9biol. (1995) 33(6):1496–1500.
   Google Scholar
• GARNER JA, COVER TL: Analysis of genetic diversity incytotoxin-producing and non-cytotoxin-producing Helicobacter pylori strains. J. Infect. Dis. (1995) 172(1):290–293.
   PubMedGoogle Scholar
• CORTHESY-THEULAZ T, PORTA N, GLAUSER M, SARAGAE, VANEY A, HAAS R, KRAEHENBUHL JP, BLUM AL, MICHETTI P: Oral immunization with Helicobacter py-lori urease B subunit as a treatment against Helicobac-ter infection in mice. Gastroenterol. (1995) 109(1):115–121.
   PubMedGoogle Scholar
• LEE CK, WELTZIN R, THOMAS WD, KLEANTHOUS H, ERMAK TH, SOMAN G, HILL JE, ACKERMAN SK, MONATH TP: Oral immunization with recombinant Helicobacter pylori urease induces secretory IgA antibodies and protects mice from challenge with Helicobacterfelis. Inf Dis. (1995) 172(1):161–172.
   PubMedGoogle Scholar
• MARCHETTI M, ARICO B, BURRONI D, FIGURA N, RAPPUOLI R, GHIARA P: Development of a mouse model of Helicobacter pylori infection that mimics human dis-ease Science (1995) 267(5204) : 1655–1658.
   Google Scholar